Q3 2024 InspireMD Inc Earnings Call Transcript
Key Points
- InspireMD Inc (NSPR) reported a 16% increase in CGUARD revenue, reaching $1.81 million for Q3 2024.
- The company achieved a 14% growth in CGUARD implants sold, totaling over 3,100 units for the quarter.
- InspireMD Inc (NSPR) has captured double-digit market share across 30 countries with its carotid stent technology.
- The company anticipates the approval and launch of CGUARD Prime in the US in the first half of 2025, which could significantly boost revenue.
- InspireMD Inc (NSPR) has strengthened its operational capabilities with a new headquarters in Miami, Florida, positioning it well for the anticipated US launch.
- Gross profit decreased by 5.6% to $414,000, with a decline in gross margin from 28.1% to 22.9% year-over-year.
- Total operating expenses increased by 46.1% to $8.9 million, driven by higher compensation, clinical, and development costs.
- The company reported a net loss of $7.9 million for Q3 2024, compared to a $5.2 million loss in the same period last year.
- Despite revenue growth, the company faces significant challenges in managing costs and achieving profitability.
- The US market entry is contingent upon FDA approval, which introduces regulatory risk and potential delays.
Please stand by your program is about to begin. Good day, everyone and welcome to the Inspire MD third quarter, 2024 earnings call. (Operator instruction) Please note this conference is being recorded. I will now turn the conference over to Charles M. Padala with LifeSci Advisors, thank you. You may begin.
Thank you, operator, and good morning, everyone. Thank you for joining us for the InspireMD third quarter, financial results and corporate update conference call.
Joining us today from InspireMD are Marvin Slosman, Chief Executive Officer and Craig Shore Chief Financial Officer, Shane Gleason, Chief Commercial Officer will also be available for Q&A. During this call management will be making forward-looking statements, not historical facts which are based upon management's current expectations, beliefs and projections. Many of which by their nature are inherently uncertain. These forward-looking statements involve risks and uncertainties that may cause actual results
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
